FLT3 and acute myeloid leukemia: The median OS was 33.4 weeks in patients with relapsed/refractory FLT3-mutated AML who were TKI naive; OS was longest in those with FLT3-ITD mutations (34 weeks) and patients aged <60 years (33.4 weeks) [26].